Analysts See $-0.64 EPS for Tetraphase Pharmaceuticals, Inc. (TTPH); Force Capital Management Lowered Visa (V) Position

February 14, 2018 - By Pete Kolinski

Force Capital Management Llc decreased Visa Inc (V) stake by 6.18% reported in 2017Q3 SEC filing. Force Capital Management Llc sold 3,900 shares as Visa Inc (V)’s stock rose 5.74%. The Force Capital Management Llc holds 59,199 shares with $6.23 million value, down from 63,099 last quarter. Visa Inc now has $270.85 billion valuation. The stock increased 1.40% or $1.66 during the last trading session, reaching $120.01. About 3.94 million shares traded. Visa Inc. (NYSE:V) has risen 20.29% since February 14, 2017 and is uptrending. It has outperformed by 3.59% the S&P500.

Analysts expect Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) to report $-0.64 EPS on March, 14.They anticipate $0.03 EPS change or 4.92% from last quarter’s $-0.61 EPS. After having $-0.63 EPS previously, Tetraphase Pharmaceuticals, Inc.’s analysts see 1.59% EPS growth. The stock decreased 59.30% or $3.22 during the last trading session, reaching $2.21. About 12.22 million shares traded or 2454.05% up from the average. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has risen 106.58% since February 14, 2017 and is uptrending. It has outperformed by 89.88% the S&P500.

Since August 17, 2017, it had 0 insider purchases, and 2 insider sales for $6.36 million activity. 49,702 shares valued at $5.65M were sold by MAHON TULLIER KELLY on Friday, December 15. MATSCHULLAT ROBERT W sold $707,561 worth of stock. CRANSTON MARY B sold $1.07M worth of stock or 10,400 shares.

Among 42 analysts covering Visa Inc. (NYSE:V), 34 have Buy rating, 0 Sell and 8 Hold. Therefore 81% are positive. Visa Inc. had 125 analyst reports since July 21, 2015 according to SRatingsIntel. Piper Jaffray maintained the shares of V in report on Thursday, July 20 with “Buy” rating. The firm has “Buy” rating given on Wednesday, December 16 by UBS. The firm has “Buy” rating by RBC Capital Markets given on Thursday, July 20. On Friday, February 2 the stock rating was maintained by Mizuho with “Buy”. The rating was maintained by Robert W. Baird on Thursday, January 18 with “Buy”. The rating was maintained by Jefferies on Monday, October 30 with “Buy”. On Thursday, January 4 the stock rating was maintained by RBC Capital Markets with “Buy”. Susquehanna maintained it with “Buy” rating and $146.0 target in Monday, January 29 report. The stock of Visa Inc. (NYSE:V) has “Outperform” rating given on Tuesday, October 25 by RBC Capital Markets. The rating was maintained by Bank of America with “Buy” on Friday, July 21.

Investors sentiment decreased to 1 in 2017 Q3. Its down 0.13, from 1.13 in 2017Q2. It dropped, as 48 investors sold V shares while 617 reduced holdings. 142 funds opened positions while 524 raised stakes. 1.64 billion shares or 1.45% less from 1.66 billion shares in 2017Q2 were reported. Jackson Square Prtnrs accumulated 9.43M shares or 4.82% of the stock. De Burlo Gru stated it has 168,700 shares or 3.93% of all its holdings. Aspen Investment Management has 9,272 shares. Bingham Osborn And Scarborough Lc owns 0.02% invested in Visa Inc. (NYSE:V) for 2,483 shares. Edgemoor Investment Advsrs has invested 0.92% in Visa Inc. (NYSE:V). Pointstate Capital LP stated it has 0.39% of its portfolio in Visa Inc. (NYSE:V). Usa Portformulas invested in 75,697 shares or 1.9% of the stock. 36,089 were accumulated by Quadrant Cap Mngmt Ltd Liability Com. Thomas Story And Son Limited Liability Company accumulated 130,565 shares. Hartline Inv Corporation reported 60,370 shares or 1.92% of all its holdings. Lpl Financial Limited invested in 0.24% or 653,029 shares. Ionic Capital Ltd Liability Corp reported 0.1% stake. Kdi Cap Prtnrs Limited Liability Corporation holds 96,704 shares. Gotham Asset Management Ltd Limited Liability Company stated it has 0.22% of its portfolio in Visa Inc. (NYSE:V). Estabrook Cap has invested 0.12% in Visa Inc. (NYSE:V).

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company has market cap of $114.03 million. The Company’s lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It currently has negative earnings. The firm has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy.

Investors sentiment increased to 2.21 in Q3 2017. Its up 0.90, from 1.31 in 2017Q2. It improved, as 10 investors sold Tetraphase Pharmaceuticals, Inc. shares while 14 reduced holdings. 19 funds opened positions while 34 raised stakes. 29.38 million shares or 42.90% more from 20.56 million shares in 2017Q2 were reported. Rhumbline Advisers holds 0% or 57,593 shares in its portfolio. Fmr Limited Liability Company accumulated 1.29 million shares. Nationwide Fund Advsrs holds 42,362 shares. Canada Pension Plan Board invested in 2.55 million shares. State Of Wisconsin Investment Board has invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Baker Bros Advsr Limited Partnership invested in 0.05% or 935,000 shares. Gabelli Funds Limited Liability Company holds 128,000 shares or 0.01% of its portfolio. Citigroup Inc has 218 shares. Tiaa Cref Inv Management Limited Co accumulated 122,422 shares or 0% of the stock. Rock Springs Capital Mngmt L P has invested 0.3% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Numeric Invsts Lc reported 1.95M shares. Renaissance Limited Liability accumulated 333,585 shares. Wade G W And stated it has 0.01% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Deutsche Bankshares Ag has invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Goldman Sachs Gru holds 0% or 47,051 shares.

Since August 17, 2017, it had 0 insider buys, and 3 sales for $203,932 activity. Dumas Jacques sold 7,155 shares worth $41,928.

Among 15 analysts covering Tetraphase Pharmaceuticals (NASDAQ:TTPH), 7 have Buy rating, 0 Sell and 8 Hold. Therefore 47% are positive. Tetraphase Pharmaceuticals had 27 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was downgraded by SunTrust to “Neutral” on Wednesday, September 9. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has “Outperform” rating given on Friday, March 10 by BMO Capital Markets. The company was downgraded on Wednesday, September 9 by Cantor Fitzgerald. The stock has “Buy” rating by Stifel Nicolaus on Wednesday, July 26. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) earned “Buy” rating by SunTrust on Thursday, November 19. The firm has “Outperform” rating by BMO Capital Markets given on Thursday, October 5. Stifel Nicolaus maintained the stock with “Buy” rating in Monday, September 11 report. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) earned “Buy” rating by FBR Capital on Monday, February 12. As per Thursday, August 6, the company rating was maintained by Stifel Nicolaus. The rating was maintained by Needham with “Buy” on Thursday, August 6.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>